Protocol Ledger

NCT06122584 · Phase III · RECRUITING

Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

Interventional Phase III clinical trial protocol NCT06122584 sponsored by ABX advanced biochemical compounds in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-06-13 Enrollment: 434 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06122584
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)434 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06122584
Protocol FieldVerified Registry Value
NCT IdentifierNCT06122584
Consolidated Lead SponsorABX advanced biochemical compounds
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment434 participants (ESTIMATED)
Registered Start Date2024-06-13
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI